Humana (NYSE:HUM) Price Target Raised to $335.00 at SunTrust Banks

Humana (NYSE:HUM) had its target price lifted by SunTrust Banks to $335.00 in a report issued on Thursday, The Fly reports. They currently have a hold rating on the insurance provider’s stock. SunTrust Banks also issued estimates for Humana’s Q4 2019 earnings at $2.22 EPS, FY2019 earnings at $17.78 EPS, Q1 2020 earnings at $4.80 EPS, Q2 2020 earnings at $5.94 EPS, Q3 2020 earnings at $5.04 EPS, Q4 2020 earnings at $2.86 EPS and FY2020 earnings at $18.64 EPS. The analysts noted that the move was a valuation call.

Several other analysts have also recently issued reports on HUM. Deutsche Bank started coverage on Humana in a report on Thursday, September 12th. They issued a hold rating and a $300.00 target price for the company. Piper Jaffray Companies upped their target price on Humana from $315.00 to $341.00 and gave the company an overweight rating in a report on Thursday, August 1st. UBS Group upped their target price on Humana from $266.00 to $317.00 and gave the company a neutral rating in a report on Thursday, August 1st. JPMorgan Chase & Co. upped their target price on Humana from $288.00 to $322.00 and gave the company an overweight rating in a report on Thursday, August 1st. Finally, Cantor Fitzgerald upgraded Humana from a neutral rating to an overweight rating and upped their target price for the company from $300.00 to $345.00 in a report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and fourteen have given a buy rating to the stock. The stock presently has an average rating of Buy and an average target price of $322.63.

Shares of HUM traded up $2.44 during trading hours on Thursday, hitting $317.58. 1,173,375 shares of the stock were exchanged, compared to its average volume of 1,220,728. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.75 and a current ratio of 1.75. Humana has a 12-month low of $225.65 and a 12-month high of $342.03. The company has a market cap of $39.82 billion, a price-to-earnings ratio of 21.83, a price-to-earnings-growth ratio of 1.27 and a beta of 0.85. The stock’s 50-day moving average price is $277.48 and its two-hundred day moving average price is $270.93.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, November 6th. The insurance provider reported $5.03 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $4.58 by $0.45. The company had revenue of $16.24 billion during the quarter, compared to analysts’ expectations of $16.15 billion. Humana had a return on equity of 22.47% and a net margin of 4.13%. The firm’s quarterly revenue was up 14.3% on a year-over-year basis. During the same period in the prior year, the business earned $4.58 EPS. On average, research analysts expect that Humana will post 17.75 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.69%. The ex-dividend date is Monday, December 30th. Humana’s dividend payout ratio is presently 15.12%.

In other news, insider Brian P. Leclaire sold 7,239 shares of the stock in a transaction on Thursday, August 22nd. The stock was sold at an average price of $289.70, for a total transaction of $2,097,138.30. Following the completion of the transaction, the insider now directly owns 12,994 shares in the company, valued at approximately $3,764,361.80. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.54% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Maverick Capital Ltd. grew its holdings in shares of Humana by 150.9% during the 2nd quarter. Maverick Capital Ltd. now owns 1,550,726 shares of the insurance provider’s stock worth $411,408,000 after purchasing an additional 932,778 shares during the period. Wells Fargo & Company MN grew its holdings in shares of Humana by 1.8% during the 2nd quarter. Wells Fargo & Company MN now owns 1,367,476 shares of the insurance provider’s stock worth $362,790,000 after purchasing an additional 24,314 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of Humana by 1.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,181,373 shares of the insurance provider’s stock worth $313,417,000 after purchasing an additional 21,207 shares during the period. Amundi Pioneer Asset Management Inc. grew its holdings in shares of Humana by 76.7% during the 2nd quarter. Amundi Pioneer Asset Management Inc. now owns 877,582 shares of the insurance provider’s stock worth $232,822,000 after purchasing an additional 380,979 shares during the period. Finally, California Public Employees Retirement System grew its holdings in shares of Humana by 8.6% during the 3rd quarter. California Public Employees Retirement System now owns 850,334 shares of the insurance provider’s stock worth $217,405,000 after purchasing an additional 67,252 shares during the period. Institutional investors and hedge funds own 92.93% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company offers medical and supplemental benefit plans to individuals. It also has contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Story: What are the Different Types of Leveraged Buyouts?

The Fly

Analyst Recommendations for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.